Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 341-349

  Stopeck, A T ^a   Hersh, E M ^a   Akporiaye, E T ^a   Harris, D T ^a   Grogan, T ^a   Unger, E ^a   Warneke, J ^a   Schluter, S F ^a   Stahl, S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOVECTIN 7; HISTOCOMPATIBILITY ANTIGEN; HLA B ANTIGEN; PLASMID VECTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE TRANSFER; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031032759     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.341     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics 1996. CA Cancer J Clin 46:9, 1995
2. Ho RC: Medical management of stage IV malignant melanoma. Medical issues. Cancer 75:735-741, 1995 (suppl 2)
3. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
4. Mukherji B, Chakraborty ND: Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 7:175-184, 1995
5. Hersey P: Melanoma vaccines. Current status and future prospects. Drugs 47:373-382, 1994
6. Kirkwood JM: Melanoma: Clinical applications: Biologic therapy with interferon-alpha and beta, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer (ed 2). Philadelphia, PA, Lippincott, 1995, pp 388-411
7. Marincola FM, Rosenberg SA: Melanoma: Clinical applications: Biologic therapy with interleukin-2, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer (ed 2). Philadelphia, PA, Lippincott, 1995, pp 250-262
8. Irie RF, Matsuki T, Morton DL: Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786-787, 1989
9. Dalgleish AG: Cancer vaccines. Eur J Cancer 30A:1029-1035, 1994
10. Lanzavecchia A: Identifying strategies for immune intervention. Science 260:937-943, 1993
11. Ruiter DJ, Mattijssen V, Broecker EB, et al: MHC antigens in human melanomas. Semin Cancer Biol 2:35-45, 1991
12. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403-450, 1993
13. Ruiter DJ, Bergman W, Welvaart K, et al: Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 44:3930-3935, 1984
14. van Duinen SG, Ruiter DJ, Broecker EB, et al: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019-1025, 1988
15. Hui K, Grosveld F, Festenstein H: Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311:750-752, 1984
16. Wallich R, Bulbuc N, Hammerling GH, et al: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-305, 1985
17. Tanaka K, Isselbacher KJ, Khoury G, et al: Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228:26-30, 1985
18. b gene. Proc Natl Acad Sci USA 85:4463-4467, 1988
19. Goodenow RS, Vogel JM, Linsk RL: Histocompatibility antigens on murine tumors. Science 230:777-783, 1985
20. Plautz GE, Yang ZY, Wu BY, et al: Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645-4649, 1993
21. Nabel GJ, Nabel EG, Yang ZY, et al: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307-11311, 1993
22. Grogan T, Rangel C, Rimsza L, et al: Kinetic-mode, automated double-labelled immunohistochemistry and in situ hybridization in diagnostic pathology. Adv Pathol Lab Med 8:99-118, 1995
23. Harris DT, LoCascio J, Bensencon FJ: Analysis of the allore-active capacity of human umbilical cord blood: implications for graft-versus-host disease. Bone Marrow Transplant 14:545-553, 1994
24. Rozman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370-374, 1991
25. Chen Q, Daniel V, Maher DW, et al: IL-10 is produced by melanoma cells and may have a role in immunosuppression mediated by melanoma. Int J Cancer 56:1-6, 1994
26. Baich CM, Soong SJ, Murad RM: A multifactorial analysis of melanoma. Diagnostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-134, 1983
27. Leong SPL, Zhou Y-M, Granberry ME, et al: Generation of cytotoxic effector cells against human melanoma. Cancer Immunol Immunother 40:397-409, 1995
28. Vogelzang NJ, Sudakoff G, McKay S, et al: A phase I study of intralesional (IL) gene therapy in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 14:242, 1995 (abstr 641)
29. Rubin J, Charboneau JW, Reading CC, et al: Phase I study of immunotherapy of hepatic metastasis of colorectal carcinoma by direct gene transfer. Proc Am Soc Clin Oncol 14:228, 1995 (abstr 589)
30. 2,-microglobulin mRNA in human colon carcinoma. J Exp Med 169:309-314, 1989
31. 2m gene expression. J Clin Invest 87:284-292, 1991
32. Morton DL, Barth A: Local therapy with biologic agents: Intralesional therapy, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer (ed 2). Philadelphia, PA, Lippincott, 1995, pp 691-704